Drug distributor McKesson and private equity firm Clayton Dubilier & Rice announced on October 6 they will take Option Care Health private in a transaction valued at $5.8 billion. The deal removes the last independent, publicly traded infusion therapy provider from U.S. equity markets and places the nation's largest home infusion network under the control of its primary pharmaceutical supplier. McKesson already holds a 71% ownership stake in Option Care through multiple joint ventures and distribution agreements dating to 2015. CD&R, which manages $70 billion in committed capital across healthcare and industrial sectors, will co-control the combined entity.
Option Care operates 350 infusion pharmacy sites across 50 states, serving approximately 200,000 patients annually with complex therapies including immunoglobulin, anticoagulation, and specialty oncology drugs. The company reported $4.8 billion in trailing twelve-month revenue as of June 2024, with adjusted EBITDA margins in the 10-11% range. McKesson's existing relationship with Option Care generated $3.2 billion in pharmaceutical product sales during fiscal 2024, making the target McKesson's second-largest single customer after CVS Health. The privatization eliminates quarterly earnings pressure on a capital-intensive business model that requires 18-24 months to achieve breakeven on new site openings.
The transaction crystallizes three structural shifts in pharmaceutical distribution. First, the integration tightens McKesson's grip on the alternate-site channel, which grew 14% annually from 2019 through 2023 as payers and health systems pushed expensive infusion therapies out of hospital outpatient departments. Second, it removes public market visibility into infusion therapy margins at a moment when biosimilar penetration in immunology is pressuring gross profit per patient. Option Care's gross margin compressed 120 basis points year-over-year in the most recent quarter, driven by adalimumab and rituximab biosimilar conversions that carry 30-40% lower reimbursement than reference biologics. Third, the deal insulates McKesson from antitrust scrutiny by formally consolidating what was already a de facto vertically integrated operation. The Federal Trade Commission declined to challenge McKesson's 2019 expansion of its Option Care joint venture, and the current transaction presents fewer competitive concerns because no new market foreclosure occurs.
Allocators should track three follow-on developments. McKesson will report fiscal Q3 earnings in late January 2025; management commentary on alternate-site growth and specialty drug margin will clarify whether additional site consolidation is planned. CD&R's healthcare portfolio includes Sedgwick, a workers' compensation administrator with 27,000 clients, and the firm historically seeks revenue synergies between platform companies within 12-18 months of acquisition close. Cross-referral agreements between Sedgwick's injury management network and Option Care's infusion sites would represent a $400-600 million annual revenue opportunity, assuming 8-12% of Sedgwick's case volume involves complex medication therapy. Finally, watch for secondary buyouts in the broader alternate-site sector. BrightSpring Health Services, a $16 billion revenue pharmacy and home health operator owned by KKR, is the only remaining scaled infusion competitor, and its ownership tenure suggests a 2025-2026 exit window.
The Option Care privatization is the second $5+ billion take-private in specialty pharmacy distribution in eighteen months, following Walgreens Boots Alliance's $6.5 billion sale of its specialty pharmacy unit to CD&R-backed Shields Health Solutions. The pattern confirms that public equity investors no longer assign premium multiples to pharmaceutical services businesses with single-digit EBITDA margins and 18-month reinvestment cycles, regardless of top-line growth rates.
The takeaway
McKesson formalizes control of the largest U.S. infusion network, eliminating public comp visibility ahead of biosimilar margin compression.
Editorial & Disclosure Notice: This article was written with artificial intelligence from public sources and is published without individual human review. Artificial intelligence and other digital tools are also used for research, analysis, editing, formatting, and production. Errors, omissions, outdated information, or inaccuracies may occur. References to companies, brands, products, services, organizations, or individuals are for informational and editorial purposes and do not imply endorsement, sponsorship, affiliation, partnership, or approval unless expressly stated. All trademarks and other intellectual property remain the property of their respective owners. Opinions, analysis, estimates, and commentary are informational only and should not be construed as financial, investment, legal, tax, medical, procurement, or other professional advice. Information may be corrected, clarified, or updated after publication. Corrections or removal requests: jenny@pops4.com.
Want the 60-second program for your specific event?
Enter your event and email — we build it and send the branded proposal before lunch. No obligation.
The branded-identity layer Chiefs of Staff and heritage CMOs route through — your name imprinted on real authorized stock, your pick of 200+ brands and 70,000 products, shipped from one accountable house. Nine editorial desks publish the intelligence those operators read before they sign.
200+authorized brands
70,000products · virtual proof on each
9 deskspublishing daily
1997one house, since
70,000 SKUs · virtual proof in 60 seconds · no platform fee · blind-shipped · ASI #217876
Your next customer won't visit your website. Their AI will.
AI assistants have quietly taken over the first step of buying — they answer from catalogs they can read and shortlist whoever can actually ship. Two questions now decide whether you exist to that buyer: can a machine read your catalog, and can you fulfill the order. Most brands fail one or both and never find out why the orders went elsewhere. The winners of this shift aren't the loudest. They're the most readable. Build for the machine that's about to do the shopping.
Built by the craft floor — apparel, media, packaging, and secure print.
This trade runs on hands, not desks. Imprint manufacturing & Komori heritage press through approved vendors · Canon high-speed secure-media operations is a craft floor — genuine Six Sigma discipline applied to ink, thread, foil, and registration, where a hundredth of an inch is the difference between a brand that reads serious and one that reads cheap. POPS4 is built by exactly those operators: independent, boots-on-the-ground engineers who carry their own book, read a client in microseconds, and put their name on every run. Beyond our own Virginia Beach floor, we work with a vetted network of craft manufacturers across the US — each meeting the highest excellence in QC standards in the industry, each a specialist in its own discipline — so apparel, hard-goods imprinting, media manufacturing, packaging, and secure printing all go to the bench built for them, coordinated from one accountable hub. Short-run from twenty-five units, volume to five hundred thousand. Two hundred authorized national brands, seventy thousand SKUs with virtual proofing on every one. Art archived for instant reorders. Net-thirty corporate terms, NDA-standard white-label — your name on the work, or none at all.
Strategy, positioning, identity, creative, and messaging — wired into an AI system that publishes and distributes on its own. Nine editorial desks generate the authority, the production house ships the physical proof, and the attribution layer tells you which post sold which SKU. What you get is an operating layer — content, catalog, and order path under one roof — that keeps working whether or not you are in the room. Built for principals who would rather own the machine than rent the agency.
Named-account programs — one desk, quiet delivery, NDA-standard.
One point of contact who already knows the file, so nothing restarts from zero between engagements. The work ships blind, under NDA, with your name on it or none at all. Built for single-family offices, heritage-house CMOs, sports-ownership groups, and the agencies that white-label our production. The relationship is the product; the merch is the proof of it.
SFO · Chief of Staff desk. Principal household, properties, aircraft, yacht, calendar, philanthropy — one file.
Shop seventy thousand products. Virtual proof on every one. 24/7.
Drop your logo on any product and see the virtual proof before asking. Quote routes direct to the desk. MCP catalog for AI agents. Celeste for the fast conversation. Full self-service checkout in development.